⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

December 15, 1996CancerOpen Access

High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma

View Full Paper

Ask AI

Bookmark

Share

Authors

GLGwynn D. LongDuke University NCNelson J. ChaoDuke University WHWendy HuPfizer (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Long et al. (1996) studied this question.

synapsesocial.com/papers/6a1fcfda707ad299c7139f4d https://doi.org/10.1002/(sici)1097-0142(19961215)78:12<2502::aid-cncr9>3.0.co;2-l

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Nonparametric Estimation from Incomplete Observations1958 · 39,539 citations
2Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients.1994 · 160 citations
3Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.1991 · 176 citations
4Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial [see comments]1992 · 190 citations
5High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.1994 · 214 citations